Results from Two Phase 3 Studies Evaluating CAMZYOS (mavacamten) for symptomatic obstructive hypertrophic cardiomyopathy (HCM) Released by Bristol Myers Squibb

New long-term follow-up results from two Phase 3 studies evaluating CAMZYOS (mavacamten), a first-in-class cardiac myosin inhibitor, in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) were recently announced by Bristol Myers Squibb.

Related Keywords

Brazil ,Netherlands ,Macau ,South Korea ,Australia ,Amsterdam ,Noord Holland ,Switzerland ,Canada ,United States ,United Kingdom ,Singapore ,Great Britain ,Milind Desai ,Amy Sehnert ,Heart Failure Clinical Development ,Vascular Thoracic Institute At Cleveland Clinic ,European Society Of Cardiology ,European Union ,York Heart Association ,Bristol Myers Squibb ,Bristol Myers ,European Society ,European Heart ,Vice President ,Total Symptom Score ,Physical Limitations ,Thoracic Institute ,New York Heart Association ,Prescribing Information ,